This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 2,440 trials Clear all
Filter by:

ONO-7913 Phase I Study (ONO-7913)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Solid Tumor
    Solid Tumor
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: ONO-7913

Eligibility
  • Ages: 20 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: ONO-7913

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Local Institution, Chuo-ku, Tokyo, Japan

Brief Summary

To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Danderyd Hospital, Danderyd, Sweden

Brief Summary

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness. Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID-19. However, data is limited to small studies and case series on severely ill patients. The proposed study assesses the safety and efficacy earlier in the course of illness, in slightly less severe patients with the possibility of detecting less severe adverse events and the potential for early treatment to hinder the development of severe disease. Plasma is collected from consenting donors who have recovered from SARS-CoV-2.

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of placebo at the schedule of day 0,28, Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Eligibility
  • Ages: 60 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of placebo at the schedule of day 0,28, Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China

Brief Summary

This study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy elderly aged 60 years and above.

A Pharmacokinetics and Safety Study of Narfurine Hydrochloride Orally Disintegrating Tablets

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Improvement of Pruritus in Hemodialysis Patients
    Improvement of Pruritus in Hemodialysis Patients
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: narfurine hydrochloride orally disintegrating tablets

Eligibility
  • Ages: 18 to 40 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: narfurine hydrochloride orally disintegrating tablets

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The First Affiliated Hospital,ZheJiang Univercity, Hanzhou, Zhejiang, China

Brief Summary

Main objective: To evaluate the pharmacokinetics of single and multiple oral administration of narfurine hydrochloride orally disintegrating tablets in Chinese healthy adult subjects. Secondary objective: To evaluate the safety profile of single and multiple oral administration of narfurine hydrochloride orally disintegrating tablets in Chinese healthy adult subjects.

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relative Bioavailability
    Relative Bioavailability
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: BLD-0409

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: BLD-0409

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Scientia Clinical Research, Randwick, New South Wales, Australia

Brief Summary

A Two-Part, Open-Label, Crossover, Bioavailability Study Comparing Tablet and Oral Solution Formulations of BLD-0409 in Healthy Volunteers

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Pruritus, Cholestasis, Kidney Failure
    Pruritus, Cholestasis, Kidney Failure
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: EP547, Drug: Placebo

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: EP547, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CMAX Clinical Research, Adelaide, South Australia, Australia

Brief Summary

This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Biliary Tract Carcinomas

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Metastatic Cancer, Solid Tumor
    Metastatic Cancer, Solid Tumor
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Sym021, Drug: Sym022, Drug: Sym023, Drug: Irinotecan Hydrochloride

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Sym021, Drug: Sym022, Drug: Sym023, Drug: Irinotecan Hydrochloride

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Colorado, Aurora, Colorado, United States

Brief Summary

The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinoma by assessing overall response rates (ORRs) per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 The study will also evaluate the safety and tolerability profile of the 3 combinations

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Facial Fine Lines
    Facial Fine Lines
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Botox, Drug: Placebo

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Botox, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Skin and Cancer Associates, LLP /ID# 225152, Miami, Florida, United States

Brief Summary

The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.

Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: COVI-VAC, Other: Placebo

Eligibility
  • Ages: 18 to 30 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: COVI-VAC, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

hVIVO, London, United Kingdom

Brief Summary

This is the first study of COVI-VAC in humans. The purpose of the study is to evaluate the safety and immune response of COVI-VAC (a live attenuated vaccine to prevent COVID-19) in healthy adults aged 18 to 30 years. Approximately 48 participants will be enrolled into 1 of 3 dose groups (low, medium, high). Within each of these dose groups, participants will be assigned randomly to receive either 2 doses of COVI-VAC 28 days apart, 2 doses of placebo (saline), or 1 dose of COVI-VAC and 1 dose of placebo. COVI-VAC or placebo is administered by drops into each nostril. Neither the participants nor the researchers will know whether COVI-VAC or placebo has been received. To assess the safety of the vaccine, each participant will record symptoms and oral temperature in a diary daily for 14 days after each dose. Safety laboratory tests, physical exams, ECGs, and a chest X-ray will also be performed, and peak expiratory flow and vital signs will be measured. Adverse events and medication use will be recorded. Blood samples and intranasal samples will be collected to assess the immune response from the vaccine.

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi D...
    Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi D...
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: TBAJ-876 Dose XXXmg for Food cohort, Drug: TBAJ-876 XXXmg for Part 2, Drug: TBAJ-876 10mg, Drug: TBAJ-876 25mg, Drug: TBAJ-876 50mg, Drug: TBAJ-876 100mg, Drug: TBAJ-876 200mg, Drug: TBAJ-876 400mg, Drug: Matching Placebo for TBAJ-876 tablet

Eligibility
  • Ages: 19 to 50 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: TBAJ-876 Dose XXXmg for Food cohort, Drug: TBAJ-876 XXXmg for Part 2, Drug: TBAJ-876 10mg, Drug: TBAJ-876 25mg, Drug: TBAJ-876 50mg, Drug: TBAJ-876 100mg, Drug: TBAJ-876 200mg, Drug: TBAJ-876 400mg, Drug: Matching Placebo for TBAJ-876 tablet

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Worldwide Clinical Trials, San Antonio, Texas, United States

Brief Summary

A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose with a Food Effect Cohort (Part 1) and Multiple Ascending Dose Study (Part 2) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects